Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Account Payables (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Change in Account Payables for 12 consecutive years, with -$5.7 million as the latest value for Q1 2026.

  • For Q1 2026, Change in Account Payables fell 263.33% year-over-year to -$5.7 million; the TTM value through Mar 2026 reached $796000.0, down 35.7%, while the annual FY2025 figure was $5.0 million, 197.54% up from the prior year.
  • Change in Account Payables hit -$5.7 million in Q1 2026 for Syndax Pharmaceuticals, down from $2.8 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $7.3 million in Q2 2025 and bottomed at -$6.7 million in Q3 2024.
  • Average Change in Account Payables over 5 years is $304352.9, with a median of $676000.0 recorded in 2022.
  • On a YoY basis, Change in Account Payables climbed as much as 262.97% in 2023 and fell as far as 829.29% in 2023.
  • Syndax Pharmaceuticals' Change in Account Payables stood at -$2.8 million in 2022, then soared by 241.53% to $3.9 million in 2023, then skyrocketed by 71.98% to $6.7 million in 2024, then tumbled by 59.07% to $2.8 million in 2025, then crashed by 308.32% to -$5.7 million in 2026.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$5.7 million, $2.8 million, and -$3.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.